Improvement in lesion extent and severity demonstrated in AD-15261
(secondary endpoint)1-3,a-c
Adolescents ≥60 kg received DUPIXENT 300 mg Q2W after a 600 mg loading dose, and adolescents <60 kg received
200 mg Q2W after a
400 mg loading dose.1
aFull Analysis Set includes all subjects randomized.1
bIn the primary analyses of the efficacy endpoints, subjects who received rescue treatment or with missing data were considered nonresponders (59% and 21% in the placebo and DUPIXENT arms, respectively).1
cA clinical responder was defined as a subject with an IGA 0 or 1 (clear or almost clear) and a reduction of ≥2 points on a 0‑4 IGA scale at Week 16 (primary efficacy outcome).1
Measuring the extent and severity of lesional signs of atopic dermatitis
EASI combines the severity of the signs of eczema and the extent of skin involvement.4
The severity of each
of 4 eczema signs is assessed on a scale
of 0 to 34
The EASI scoring system uses a defined process to grade the severity of the signs of eczema (erythema, edema/papulation, excoriation, and lichenification) and the extent to which the patient is affected. The extent of lesions in each body region is evaluated based on the percentage of involvement and is given a value between 0 and 6. Each body region value is then weighted by a corresponding multiplier; lower extremities are weighted more while head and neck are weighted the least.4
Each region gets a total region score:
Severity Score x Area Score x Multiplier = Region Score
The final EASI score is the sum of all 4 region scores. The composite score, on a scale from 0 to 72, determines the severity of the signs of eczema and the extent to which the patient is affected.4,d
An improvement of at least 75% in lesion extent and severity (EASI-75) from baseline is a clinically meaningful change.1
In patients ≥8 years of age, the multipliers for the head and neck are 0.1, the trunk is 0.3, the upper extremities are 0.2, and the lower extremities are 0.4.4
READY TO PRESCRIBE DUPIXENT?